Patents by Inventor Mark Frigerio
Mark Frigerio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230173092Abstract: The present invention relates to antibody-drug conjugates comprising (i) an antibody or antigen-binding fragment thereof, (ii) a polymer comprising a particular repeat unit comprising an amino acid derivative, which is covalently bound to one or more biologically active moieties, such as small molecule drugs, optionally via a linker, and (iii) a polymer-antibody linker moiety which is covalently bound to both the polymer and the antibody or antigen-binding fragment thereof. Additionally, the present invention relates to pharmaceutical compositions comprising the antibody-drug conjugates and to use of the antibody-drug conjugates in medicine.Type: ApplicationFiled: May 26, 2021Publication date: June 8, 2023Applicant: SPIREA LIMITEDInventors: Myriam OUBERAI, Neil SIM, James FLEMING, Nicolas CAMPER, Mark FRIGERIO
-
Publication number: 20220062436Abstract: Specific conjugates containing auristatins and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates. Also described are specific conjugates of drugs and a binding protein or peptide in which more than one copy of the drug is present.Type: ApplicationFiled: September 17, 2021Publication date: March 3, 2022Applicant: ABZENA (UK) LIMITEDInventors: John BURT, Antony GODWIN, Mark FRIGERIO, George BADESCU
-
Patent number: 10835616Abstract: The invention relates to novel conjugating reagents capable of reaction with at least one nucleophile present in a peptide or protein, which contain at least one leaving group which is lost on reaction with said nucleophile, in which the leaving group includes a portion —(CH2CH2O)n—, in which n is a number of six or more; and novel processes for the preparation of conjugates containing peptides or proteins made using such reagents.Type: GrantFiled: October 8, 2015Date of Patent: November 17, 2020Assignee: POLYTHERICS LIMITEDInventors: Antony Godwin, George Badescu, Matthew Bird, Penny Bryant, David Morris, Mark Frigerio
-
Publication number: 20200268885Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.Type: ApplicationFiled: March 3, 2020Publication date: August 27, 2020Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Mark Frigerio
-
Publication number: 20170304461Abstract: The invention relates to novel conjugating reagents capable of reaction with at least one nucleophile present in a peptide or protein, which contain at least one leaving group which is lost on reaction with said nucleophile, in which the leaving group includes a portion —(CH2CH2O)n—, in which n is a number of six or more; and novel processes for the preparation of conjugates containing peptides or proteins made using such reagents.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, George Badescu, Matthew Bird, Penny Bryant, David Morris, Mark Frigerio
-
Publication number: 20170290925Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.Type: ApplicationFiled: October 8, 2015Publication date: October 12, 2017Applicant: POLYTHERICS LIMITEDInventors: Antony Godwin, Mark Frigerio
-
Publication number: 20150290342Abstract: Specific conjugates containing auristatins and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates. Also described are specific conjugates of drugs and a binding protein or peptide in which more than one copy of the drug is present.Type: ApplicationFiled: October 11, 2013Publication date: October 15, 2015Inventors: John Burt, Antony Godwin, Mark Frigerio, George Badescu
-
Publication number: 20150283259Abstract: Specific conjugates containing maytansines and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates.Type: ApplicationFiled: October 11, 2013Publication date: October 8, 2015Applicant: POLYTHERICS LIMITEDInventors: John Burt, Antony Godwin, Mark Frigerio, George Badescu
-
Publication number: 20130310411Abstract: The present invention relates to novel acridine derivatives of formula (I), or pharmaceutically acceptable salts thereof, which are inhibitors of the telomerase enzyme function. These compounds are useful for the treatment cellular proliferation disorders, such as cancer.Type: ApplicationFiled: September 29, 2011Publication date: November 21, 2013Applicant: PHARMINOX LIMITEDInventors: Marc Geoffery Hummersone, David Cousin, Mark Frigerio
-
Publication number: 20110130386Abstract: A compound of formula (I) wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1 and RN2 are selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms.Type: ApplicationFiled: April 24, 2009Publication date: June 2, 2011Inventors: Mark Frigerio, Heather Mary Ellen Duggan, Marc Geoffrey Hummersone, Keith Allan Menear, Niall Morrison Barr Martin, Celine Cano, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle
-
Patent number: 7696203Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N; and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.Type: GrantFiled: April 13, 2006Date of Patent: April 13, 2010Assignees: Kudos Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Keith Allan Menear, Marc Geoffrey Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Kappusamy Saravanan, Marine Desage-El Murr
-
Publication number: 20090042865Abstract: A compound of formula I: wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X is CH or N; n is 1 or 2; RC1 and RC2 are independently selected from H and methyl; when X is N, RX is selected from the group consisting of H, and optionally substituted C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, acyl, ester, amido and sulfonyl; and when X is CH, RX is selected from the group consisting of H, and optionally substituted C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl, acyl, ester, amido, sulfonyl, amino and ether.Type: ApplicationFiled: July 18, 2008Publication date: February 12, 2009Inventors: Mark Frigerio, Marc Geoffrey Hummersone, Keith Allan Menear, Christine Sarah Bailey, Heather Mary Ellen Duggan, Sylvie Gomez, Niall Morrison Barr Martin
-
Publication number: 20060264427Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, HiIary Calvert, Nicola Curtin, Kappusamy Saravanan, Marine Desage-El Murr
-
Publication number: 20060264623Abstract: Compounds of formula l: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Marine Desage-El Murr